Criteria for assessing evidence for biomarker-targeted therapies in rare cancers-an extrapolation framework.

This framework will allow systematic assessment, standardize regulatory, reimbursement and clinical decision-making, and facilitate transparent discussions between key stakeholders in drug assessment for rare biomarker-defined cancers.